Sanctuary Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sanctuary Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$277K	Sell	4,841 -3,924	-45%	-$215K	﹤0.01%	2382
2026 Q1	$495K	Sell	8,765 -586	-6%	-$34.2K	﹤0.01%	1788
2025 Q4	$556K	Sell	9,351 -14,489	-61%	-$789K	﹤0.01%	1662
2025 Q3	$1.29M	Buy	23,840 +17,464	+274%	+$999K	0.01%	1142
2025 Q2	$351K	Buy	6,376 +3,386	+113%	+$199K	﹤0.01%	1825
2025 Q1	$211K	Sell	2,990 -2,055	-41%	-$138K	﹤0.01%	2006
2024 Q4	$322K	Sell	5,045 -16,288	-76%	-$1.09M	﹤0.01%	1947
2024 Q3	$1.37M	Sell	21,333 -710	-3%	-$59.3K	0.01%	1094
2024 Q2	$1.78M	Buy	+22,043	New	+$1.84M	0.01%	872

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sanctuary Advisors's BMRN Position: Q2 2026 in Review

Sanctuary Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 45% in Q2 2026, selling an estimated $215K and leaving 4,841 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #2382.

Sanctuary Advisors first reported a position in BMRN in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.78M in Q2 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Sanctuary Advisors held 4,841 shares of BioMarin Pharmaceuticals worth $277K as of Q2 2026.
Sanctuary Advisors sold 3,924 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $215K.
BioMarin Pharmaceuticals made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #2382 holding.
Sanctuary Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Sanctuary Advisors's BioMarin Pharmaceuticals position peaked at $1.78M in Q2 2024.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.